Vaccines

The rise of Shingrix as a first-choice prophylaxis for shingles has lead to increased demand as the manufacturer commits to ramping up production.

Vaccine-preventable disease outbreaks are on the rise and social media has a responsibility to help rein it in

With 6 ongoing outbreaks, cases reported across 10 states, and the FDA commissioner contemplating federal intervention, measles remains at the forefront of collective consciousness.

As flu activity remains elevated in all regions of the United States for the fifth week in a row, a new study quantifies the impact of flu vaccination last season.

Post-licensure safety data on recombinant zoster vaccine (Shingrix) is consistent with pre-licensure clinical trial data, although the CDC cautions that the immunization is still in the “early uptake period.”

The FDA approved the vaccine in 2016 for adults between the ages of 18 and 64 who are traveling to areas of active cholera transmission.

With early season flu vaccination rates up from 2017-2018 early season rates, new pediatric influenza deaths around the country are prompting health officials to call for even higher vaccination rates.

The vaccine is approved as a 3-dose series, which consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.

TY014 is the first candidate drug to be evaluated in clinical trials for the treatment of yellow fever.

The results of a new Dutch study suggest a rationing protocol does not diminish the effectiveness of the vaccine.

A new survey has found that 34% of US parents are not planning to have their child vaccinated against influenza.

Investigators have found that children who received a flu shot in consecutive years did not see a decline in vaccine effectiveness.

Keeping communities safe from potentially deadly viruses is everyone’s responsibility.

New outbreaks of rubella and troubling data on influenza highlight the importance of vaccination.

Sanofi Pasteur’s dengue vaccine (Dengvaxia) is moving one step closer to being approved in the United States as the FDA just accepted a Biologics License Application for the vaccine.

In 2017, 47 outbreak cases of mumps were reported in the Denver Metropolitan area among individuals who attended Marshallese church events.

An eVLP cytomegalovirus (CMV) vaccine was found to be safe and immunogenic at very low doses in healthy seronegative adults.

The new vaccine schedule is 7 days between doses for adults aged 18 to 65, instead of the standard 28 days.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

New surveillance report sheds light on meningococcal disease rates among HIV-infected MSM.

Dale N Gerding, MD, provides insight about prevention options for C diff that are expected in the future.

Colleen Kelley, MD, discusses the possibility of an HIV vaccine and current progress being made in HIV prevention.

Hepatitis A outbreaks are active in 13 states across the United States, yet vaccination is required in only a fraction of them.

Investigators find that severe hospitalization cases of varicella still occur in vaccinated children, yet not vaccinating against the virus confers the greatest threat.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A social media campaign initiated in Russia may be sowing the seeds of debate surrounding vaccine safety, causing new outbreaks of measles globally.

A universal flu vaccine candidate elicits protective response in mice against multiple strains of the virus.

New recommendations from the CDC's Advisory Committee on Immunization Practices reveal that health care providers have the intranasally-administered live attenuated influenza vaccine (LAIV) among their arsenal of available vaccines for the 2018-2019 flu season.

The Democratic of the Congo Ministry of Health has authorized the use of 5 experimental Ebola treatments as more than 100 cases of Ebola are reported.

A new study reveals that the quadrivalent HPV catch-up vaccine was most effective against cancer risk in women who received the first dose between the ages of 14 and 20 years.